8-K: Certara to Acquire Chemaxon, Expanding Drug Discovery Software Portfolio

Certara, Inc. has announced a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software, to enhance its drug discovery capabilities.

Summary

• Certara, Inc. has agreed to acquire Chemaxon, a company specializing in cheminformatics software.
• The acquisition is expected to close in the second half of 2024, pending regulatory approvals and other closing conditions.
• Chemaxon's software is used for chemical structure drawing, property prediction, search, and analysis.
• This acquisition will strategically position Certara in the drug discovery biosimulation market.
• Chemaxon is expected to generate over $20 million in software revenue in 2024.
• Chemaxon's revenue growth is comparable to Certara's software business, and its adjusted EBITDA margin is expected to approach Certara's corporate average by the end of 2025.
• Certara has reiterated its 2024 financial guidance, excluding Chemaxon, consistent with the guidance provided on May 7, 2024.
• Following the transaction close, Certara will update its 2024 guidance to include Chemaxon's contribution and expects to maintain its 2024 adjusted EBITDA margin guidance of 31-33%.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with the strategic acquisition and reiteration of financial guidance. The acquisition is expected to enhance Certara's market position and capabilities.

Positives

• The acquisition of Chemaxon will expand Certara's capabilities in drug discovery.
• The combined entity will offer a comprehensive data and predictive analytics platform.
• Chemaxon's revenue and growth profile are comparable to Certara's software business.
• The acquisition is expected to enhance prediction and analytical capabilities in drug discovery.
• The combined solutions aim to reduce drug development costs and time to market.

Risks

• The acquisition is subject to regulatory approval and other customary closing conditions.
• Actual results may differ materially from forward-looking statements due to various factors.
• The company has not reconciled the forward-looking non-GAAP guidance to the most directly comparable GAAP measures.

Future Outlook

Certara will update its 2024 guidance to include Chemaxon's contribution following the transaction close and expects to maintain its 2024 adjusted EBITDA margin guidance of 31-33%.

Management Comments

• William Feehery, CEO of Certara, stated that the combination of Chemaxon and Certara unites two complementary businesses with a shared mission of reducing drug development costs and risks.
• Richard Jones, CEO of Chemaxon, said that together they will offer clients the ability to broadly conduct in-silico research to inform better decision-making at every phase of development.

Industry Context

This acquisition reflects a trend in the pharmaceutical industry towards leveraging data and predictive analytics to improve drug discovery and development processes. It positions Certara to compete more effectively in the growing market for biosimulation software.

Comparison to Industry Standards

• Certara's acquisition of Chemaxon is similar to other strategic moves by companies in the life sciences software sector to expand their offerings and market reach.
• Companies like Schrödinger and Dassault Systèmes also offer software solutions for drug discovery and development, and this acquisition positions Certara to better compete with them.
• The expected revenue and EBITDA growth of Chemaxon is in line with industry standards for software companies in the life sciences sector.

Stakeholder Impact

• Shareholders are likely to view the acquisition positively due to the potential for increased revenue and market share.
• Employees of both Certara and Chemaxon may experience changes as the companies integrate.
• Customers of both companies will have access to a broader range of solutions.
• Suppliers and creditors may see changes in their relationships with the combined entity.

Next Steps

• The transaction is expected to close in the second half of 2024.
• Certara will update its 2024 guidance to include Chemaxon's contribution following the transaction close.

Key Dates

Keywords

drug discovery, cheminformatics, biosimulation, acquisition, software, predictive analytics, EBITDA, revenue, Certara, Chemaxon